ORLANDO, Fla., Jan. 22, 2025 (GLOBE NEWSWIRE) — Arnie's, a bold new natural wellness brand inspired by Arnold Palmer's legacy of performance, embodies the unstoppable spirit that made him a global icon. Created in partnership with Arnold Palmer Enterprises and leading CBD Manufacturer Naternal, Arnie's debuts with a premium collection of topicals designed to help […]
(NYSE:HRB), KANSAS CITY, Mo., Jan. 22, 2025 (GLOBE NEWSWIRE) — The millions of Americans with revenue-generating side hustles and casual sellers may be in for a big surprise this January–an unexpected tax form called the 1099-K. Payment platforms, apps and online marketplaces must issue a Form 1099-K to anyone who received $5,000 or more in
(NASDAQ:ALXO), Mr. Shantharam is a proven biotech industry executive with over two decades of senior leadership experience in finance, commercial and corporate operations Dr. Klencke is a seasoned clinical leader in oncology drug development with more than 20 years of industry experience Dr. Takimoto brings a distinguished track record in oncology and drug development with
(NASDAQ:MATW), PITTSBURGH, Jan. 22, 2025 (GLOBE NEWSWIRE) — Matthews International Corporation (NASDAQ GSM: MATW) (“Matthews” or the “Company”) today sent a letter to its shareholders emphasizing the Company's commitment to long-term value creation. Key highlights from the letter include: Your Board has taken decisive actions to enhance long-term shareholder value – particularly the strategic sale
(NASDAQ:LSTA), Cohort A data to be presented in a poster session at the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium Data reported positive trend in overall survival, including 4 complete responses observed in the certepetide treatment group compared to none in placebo group Data from Cohort B expected in the coming months, with
(NASDAQ:PULM), SAN DIEGO, Jan. 22, 2025 (GLOBE NEWSWIRE) — Cullgen Inc. (“Cullgen”), a privately-held, clinical-stage biopharmaceutical company applying its proprietary targeted protein degradation uSMITE(TM) platform to discover and advance therapeutics for the treatment of cancer and other diseases, today announced that it has begun dosing in human subjects to evaluate its potential first-in-class, oral, pan-TRK
Registry will use HeartFlow FFRCT and Plaque Analysis to help inform strategies for prevention, earlier detection and improved care for former NFL athletes at high risk for coronary artery disease MOUNTAIN VIEW, Calif. and GREENWOOD VILLAGE, Colo., Jan. 22, 2025 (GLOBE NEWSWIRE) — HeartFlow, Inc., the global leader in non-invasive artificial intelligence (AI) heart care
(NasdaqGM:AVDL), DUBLIN, Ireland, Jan. 22, 2025 (GLOBE NEWSWIRE) — Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that Sev Melkonian has joined the company as Vice President of Patient Services, Distribution, and Reimbursement. Mr. Melkonian has extensive industry experience building and leading healthcare operations and patient
(NYSE:TRU), NEW ORLEANS, Jan. 22, 2025 (GLOBE NEWSWIRE) — Over the coming year, many consumers considering an auto loan or lease may be reentering the market with far more complicated credit pictures than they did, even just a few years ago. The findings come from a new analysis released today by TransUnion (NYSE: TRU) in
DURHAM, N.C., Jan. 22, 2025 (GLOBE NEWSWIRE) — IMMvention Therapeutix, Inc., an early-stage biotechnology company focused on discovering and developing human therapeutics, today announced a strategic collaboration and license agreement with Novo Nordisk A/S to co-develop oral therapies for sickle cell disease (SCD) and other chronic conditions. The partnership will leverage IMMvention's investigational small-molecule BACH1